Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
NCT07389629
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +16 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, China